A recent report from Renub Research, titled “Adult Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028,” offers a thorough analysis of the industry and market share knowledge. The report also includes research on regions, competitors, and the recent expansion of the adult vaccine market.
A CAGR of 6.01% is anticipated for the adult vaccine market between 2022 and 2028. One of the most important scientific developments of the twenty-first century has been the creation of safe and effective vaccines against diseases that significantly increase morbidity and mortality. New vaccines for conditions like COVID-19, tuberculosis, malaria, HIV/AIDS, dengue fever, and other illnesses are rapidly entering the market. Injectable treatments that prevent diseases like HIV, cardiometabolic disease, and common cancers are also being taken-into-account as part of the broadened definition of vaccines. Adult Vaccine Market size is anticipated to reach US$27.65 Billion by 2028, driven by rising preventive healthcare awareness, an increase in the prevalence of infectious diseases among adults, and government campaigns to encourage adult vaccination.
The prevalence of infectious diseases like influenza, hepatitis, zoster, etc., as well as government campaigns to promote immunization, are the primary factors driving the adult vaccine market’s growth. The government’s growing partnerships with pharmaceutical and biotechnology companies to develop novel vaccines will also aid the adult vaccine market’s future growth.
Non-governmental organizations (NGOs) are also taking on the responsibility of educating and enticing adults to get the recommended vaccinations, in addition to governments. The involvement of numerous The WHO and UNICEF have published guidelines on creating a national immunization plan in order to guarantee vaccination for everyone around the world. All of these recent events are anticipated to have a significant impact on the global adult vaccine market’s expanding demand for adult vaccines.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php
Pneumococcal disease has emerged as the risk factor with the quickest growth rate within the adult vaccine market.
The prevalence of adult pneumococcal disease is rising, especially in older people and people with underlying medical conditions, and this has led to an increase in the demand for adult vaccines. More recent pneumococcal vaccines, such as the 13-valent pneumococcal conjugate vaccine (PCV13), are demonstrating greater efficacy in preventing the illness. The market is expanding as a result of rising adult awareness of the advantages of vaccinations as well as initiatives from the public and private sectors to boost vaccination rates. The aging population and the creation of new pneumococcal vaccines also contribute to the market’s expansion. Pneumococcal vaccination can help prevent potentially fatal conditions brought on by the Streptococcus pneumoniae bacteria, so market expansion for the vaccine is essential for public health overall.
Disease wise – Adult Vaccine Market has been covered from 10 viewpoints
- Travel & Misc
Adult populations who have received an influenza vaccine will increase significantly in the future.
The prevalence of influenza is rising in adults, especially in older people and people with underlying medical conditions. Influenza is a highly contagious respiratory illness that can result in serious complications and even death. The quadrivalent influenza vaccine FluQuadri, for example, has increased efficacy, which is helping the market expand. The benefits of vaccination are becoming more widely known among adults, and efforts by the public and private sectors to boost vaccination rates are additional motivating factors. The market for influenza vaccines is also anticipated to grow as a result of the creation of new vaccines, aging populations, and the rising prevalence of chronic diseases. Since vaccination greatly reduces the likelihood of influenza transmission and its serious consequences, market and volume expansion is crucial for public health.
Disease wise – Numbers of Vaccinated Adults has been covered from 9 viewpoints
The adult vaccine market is currently growing at the fastest rate in India.
A rise in illnesses like pneumonia, meningitis, and HIV/AIDS has occurred recently due to India’s large and diverse population being susceptible to a wide range of infectious diseases. As a result, there is a rising need for vaccines to fend off these illnesses. Indians are becoming more aware of the advantages of vaccination, and this has led to a rise in demand as people realize how important vaccines are for both disease prevention and saving lives. Government programs, such as the National Adult Immunization Program (NAIP), which was introduced in 2017, have succeeded in raising adult population vaccination rates and awareness. Moreover, the development of new vaccines tailored for adults, providing protection against various diseases like pneumonia, meningitis, and HPV, has further bolstered demand in the adult vaccine market in India.
Country – Adult Vaccine Market has been covered from 21 viewpoints
- North America
1.1 United States
- Latin America
3.1 United Kingdom
- Asia Pacific
4.5 South Korea
- Middle East & Africa
5.1 Saudi Arabia
5.3 South Africa
- Rest of the World
GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited are significant players in the fiercely competitive adult vaccine market worldwide.
Company Insights have been covered from 3 viewpoints:
- Recent Development
- GlaxoSmithKline plc
- AstraZeneca plc
- Sanofi Pasteur
- Pfizer Inc
- CSL Limited
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)